240,311 Shares in ImmunityBio, Inc. (NASDAQ:IBRX) Bought by Marshall Wace LLP

Marshall Wace LLP acquired a new stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 240,311 shares of the company’s stock, valued at approximately $615,000.

A number of other institutional investors also recently bought and sold shares of the company. XTX Topco Ltd grew its stake in shares of ImmunityBio by 14.0% during the 4th quarter. XTX Topco Ltd now owns 105,883 shares of the company’s stock valued at $271,000 after purchasing an additional 12,973 shares during the period. Barclays PLC boosted its holdings in shares of ImmunityBio by 9.8% in the fourth quarter. Barclays PLC now owns 396,484 shares of the company’s stock worth $1,015,000 after buying an additional 35,448 shares during the last quarter. Raymond James Financial Inc. bought a new stake in ImmunityBio during the fourth quarter valued at approximately $172,000. Capula Management Ltd purchased a new stake in ImmunityBio during the fourth quarter valued at approximately $154,000. Finally, Rathbones Group PLC raised its position in ImmunityBio by 21.8% in the fourth quarter. Rathbones Group PLC now owns 89,420 shares of the company’s stock worth $229,000 after acquiring an additional 16,000 shares during the period. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Stock Performance

IBRX opened at $2.54 on Friday. The stock has a market cap of $2.17 billion, a price-to-earnings ratio of -2.76 and a beta of 0.51. The firm’s fifty day moving average is $2.78 and its 200 day moving average is $3.43. ImmunityBio, Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $10.01.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.11. The business had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $8.74 million. On average, equities research analysts predict that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Analyst Ratings Changes

IBRX has been the subject of a number of recent research reports. BTIG Research initiated coverage on shares of ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of ImmunityBio in a report on Monday, April 28th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $30.00 price objective on shares of ImmunityBio in a research note on Wednesday, April 23rd. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $12.19.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.